Physician profile
Steve Girisgen
NPI 1295788859
$4,843.72
in general payments reported to CMS, 2019-2025
10 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,723 · 2021: $330 · 2022: $293 · 2023: $149 · 2024: $90.25 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,769.96 | 2019-2025 | Clariti Contact Lens, Cvi Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $231.05 | 2019 | |
| Abb Con-Cise Optical Group LLC | $231.02 | 2019 | |
| Bausch & Lomb Americas INC. | $148.62 | 2023 | Infuse |
| Allergan, INC. | $147.59 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $127.14 | 2021 | |
| Lkc Technologies, INC. | $121.05 | 2025 | |
| Maculogix, INC. | $39.54 | 2019-2021 | |
| Alcon Research LLC | $16.52 | 2019 | |
| Alcon Vision LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Girisgen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.